⁶⁴Cu and ⁴⁷Sc (n,p) Cross-Section Measurements for Medical Radionuclide Production

A.S. Voyles^a, M.S. Basunia^b, J.C. Batchelder^b, J.D. Bauer^c,

L.A. Bernstein^{a,b}, E.F. Matthews^a, M.A. Unzueta^a

31 August 2016 WTTC '16



^a The University of California, Berkeley – Department of Nuclear Engineering





^b Lawrence Berkeley National Laboratory

^c Lawrence Livermore National Laboratory

Why Should You Care?



Why Should You Care?

- **Emerging medical radionuclides**
 - ⁶⁴Cu (t_{1/2} = 12.7 hr) 61% β ⁺ to ⁶⁴Ni, 39% β ⁻ to ⁶⁴Zn
 - ⁴⁷Sc (t_{1/2} = 3.35 d) β ⁻ to ⁴⁷Ti, with 159-keV y

Promising Prospects for ⁴⁴Sc-/⁴⁷Sc-Based Theragnostics: Application of ⁴⁷Sc for Radionuclide Tumor Therapy in Mice

Cristina Müller¹, Maruta Bunka^{2,3}, Stephanie Haller¹, Ulli Köster⁴, Viola Groehn⁵, Peter Bernhardt^{6,7}, Nicholas van der Meulen², Andreas Türler^{2,3}, and Roger Schibli^{1,8}

¹Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland; ²Laboratory of Radiochemistry and Environmental Chemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland; ³Laboratory of Radiochemistry and Environmental Chemistry, Department of Chemistry and Biochemistry University of Bern, Bern, Switzerland; ⁴Institut Laue-Langevin, Grenoble, France; ⁵Merck and Cie, Schaffhausen, Switzerland; ⁶Department of Radiation Physics, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ⁷Department of Medical Physics and Medical Bioengeneeric University Hospital, Gothenburg, Sweden; and 8Department of Chemistry and Applied Biosciences, ETH Zuric

In Vivo Evaluation of Pretargeted ⁶⁴Cu for Tumor Imaging and Therapy

Michael R. Lewis, PhD1; Mu Wang, MD1; Donald B. Axworthy, BS2; Louis J. Theodore, PhD2; Robert W. Mallet, BS2; Alan R. Fritzberg, PhD2; Michael J. Welch, PhD1; and Carolyn J. Anderson, PhD1


¹Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri; and 2NeoRx Corporation, Seattle, Washington




3

Why Should You Care?


- Emerging medical radionuclides
 - ⁶⁴Cu (t_{1/2} = 12.7 hr) 61% β ⁺ to ⁶⁴Ni, 39% β ⁻ to ⁶⁴Zn
 - ⁴⁷Sc (t_{1/2} = 3.35 d) β ⁻ to ⁴⁷Ti, with 159-keV γ
- Nuclear data as fundamental tools














Foils Used	Metal Purity	Abundance (a/o)	Foil Density (mg/cm²)
^{nat} ln	> 99.999%	¹¹³ In (4.29%), ¹¹⁵ In (95.71%)	365.5
^{nat} Zn	> 99.99%	⁶⁴ Zn (49.17%)	714.1
^{nat} Ti	99.999%	⁴⁷ Ti (7.44%)	450.6















Ortec 80% HPGe detector





Ortec Planar LEPS detector

























$$N_{A} = \phi(\overline{E})\sigma(\overline{E})$$










$$N_A = \int_{E_0}^{E_f} \frac{d\phi}{dE} \sigma(E) dE$$














10

0

EXFOR Data


3


Neutron Energy (MeV)

This Work (relative to ^{115m}In)

5

Future Work





0.05

1.58

1.83

0.31

0.05

0.00

2.18

0.44

4.47E+03

1.36E+05

1.58E+05

2.66E+04

4.39E+03

1.87E+01

1.88E+05

3.77E+04

101 1/4"

32P

47CA

64Cu

67Cu

89Sr

161Tb

166Ho

169Er

175Yb

177Lu

-928

182

203

221

-718

215

-289

-25

-189

189

-1073

429

311

281

291

25

190

0

1079

0

0

0

11.24%

52.19%

100%

18.89%

33.50%

100%

97.40%

18.60%

285.94

103.18

363.543

75.57

1379.4

109.8


396.3


208.4

Future Work

(p/d/α, x) and (n,x) Cross Section

Measurements at the LBL 88 Inch Cyclotron





Acknowledgements

This work has been carried out at the University of California, Berkeley, and performed under theauspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under contract DE-AC52-07NA27344 and Lawrence Berkeley National Laboratory under contract # DE-AC02-05CH11231. Funding has been provided from the US Nuclear Regulatory Commission and the US Nuclear Data Program.

H. F. Aly et al., Microchim. Acta, vol. 59, no. 1, 1971.

K. S. Bhatki et al., J. Radioanal. Chem., vol. 2, no. 1–2, 1969.

T. H. Bokhari et al., J. Radioanal. Nucl. Chem., vol. 283, no. 2, 2010.

J. F. Briesmeister et al., Los Alamos National Laboratory, 1986.

M. B. Chadwick, et al., Nucl. Data Sheets, vol. 107, no. 12, 2006.

A. J. Koning et al., AIP Conference Proceedings, 2005, vol. 769, no. 2.

H. Liskien et al., Nucl. Data Tables, vol 11, 1973.

M. R. Lewis et al., J. Nucl. Med., vol. 44, no. 8, Aug. 2003.

C. Müller et al., J. Nucl. Med., vol. 55, no. 10, Oct. 2014.

N. Otuka et al., Nucl. Data Sheets, vol. 120, 2014.

L. Pietrelli et al., J. Radioanal. Nucl. Chem., vol. 157, no. 2, 1992.

S. M. Qaim et al., IAEA Technical Reports Series No. 473, 2011.

D. Updegraff et al., "Nuclear Medicine without Nuclear Reactors or Uranium Enrichment," 2013.

